Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SAGA complex-associated factor 29 (SGF29)
- Target
- SGF29
- Molecular classification
- Chromatin modulator, Histone modification reader (specifically, an H3K4me2/3 reader via tandem Tudor domains), SAGA and ATAC complex subunit
01
Overview
SAGA complex-associated factor 29 (SGF29) is a component of the SAGA (Spt-Ada-Gcn5 acetyltransferase) and ATAC (Ada-Two-A-containing) transcriptional coactivator complexes, where it functions as a “reader” of methylated histone H3 lysine 4 (H3K4me2/3) via its tandem Tudor domains. SGF29 plays an essential role in recruiting the SAGA complex to chromatin, linking H3K4 methylation to histone H3 acetylation, and thereby enabling the transcriptional activation of genes including those required for the cellular stress response and cellular aging programs. SGF29 is characterized by an N-terminal coiled-coil domain and C-terminal tandem Tudor domains and is crucial for establishing a poised chromatin state at active promoters, as well as for organizing phase-separated nuclear condensates during cellular senescence, which helps coordinate the transcriptional landscape during aging. There are currently no drugs that directly target SGF29, nor is it recognized as a therapeutic target in the same sense as enzymes, receptors, or transporters.
- Other names
- SAGA-associated factor 29CCDC101FLJ32446TDRD29Coiled-coil domain-containing protein 101STAF36SAGA-associated factor 29 homolog (yeast)
02
Biological functions
Recognition of H3K4me2/3 histone marksRecruitment of the SAGA complex to target genomic lociRegulation of histone H3 acetylation and gene activationCoordination of epigenetic marks for transcriptional activation of stress and aging-associated genesFacilitation of phase separation in the nucleus, contributing to compartmentalized transcriptional regulation during cellular senescence
03
Disease associations
Cellular/replicative aging (senescence)Potential involvement in stress response (ER stress)Cancer (indirect, as part of chromatin remodeling processes but not as a primary cancer driver)
Beyond the preview
Go deeper on SAGA complex-associated factor 29 (SGF29).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SAGA complex-associated factor 29 (SGF29).